Navigation Links
Patients Who Bring Health Information from the Internet Get More Time with Doctor

94% of physicians report that patients bring health information from the Internet to discuss during office visits. The majority of physicians who have patients discussing information in the office report they spend more time with these patients as a result.

New York, NY (PRWEB) July 10, 2008 -- An increasing number of "healthcare overachievers" are bringing health information from the Internet to the doctor's office to discuss during the office visit. In fact, virtually all physicians report at least some of their patients arrive armed with health information from the Internet, according to the latest physician market research study released by pharmaceutical market research company Manhattan Research. These patients are being rewarded for their efforts, as the majority of physicians report that they spend more time with the patient as a result of their bringing information in to the office visit.

"The Internet has empowered consumers to take an increasingly active role in their healthcare management and their relationship with the physician," says Meredith Abreu Ressi, VP of research at Manhattan Research. "The conversation with the physician used to be a one-way, didactic interaction. But as consumers are increasingly bearing the responsibility for their healthcare costs and decisions, this balance of power is shifting. The Internet is a key tool consumers use to educate themselves on treatment options, and some empowered consumers are discussing their findings with their physician."

The trends in the article are derived from Taking the Pulse® v8.0, one of Manhattan Research's U.S. physician market research and advisory services. Topics from this year's study include physician Web 2.0, non-personal selling, pharma CRM, product site visitation, mobile adoption, search engine use, electronic medical record adoption, and more.

Learn more U.S. Physician Market Trends
Download the Electronic Medical Records White Paper
Sign up for Manhattan Research's pharma newsletter

About Taking the Pulse® v8.0
Taking the Pulse® v8.0 was conducted via telephone and online survey methodology in Q1 2008 with a nationally representative sample of 1,832 practicing U.S. physicians.

In addition to providing physician market trends, clients can further segment Taking the Pulse® v8.0 to derive statistically relevant insight across the following specialties: Allergists, Cardiologists, Dermatologists, Electro Physiologists, Emergency Medicine, Endocrinologists, Gastroenterologists, Surgeons, Hematology Oncologists, Infectious Disease Specialists, Medical Oncologists, Nephrologists, Neurologists, Obstetrics/Gynecologists (OB/GYNs), Ophthalmologists, Orthopedic Surgeons, Pediatricians, Primary Care Physicians (General Practice, Family Practice and Internal Medicine), Psychiatrists, Pulmonologists, Radiologists, Rheumatologists and Urologists.

Other Manhattan Research Products and Services
Manhattan Research conducts annual research studies among physicians and consumers, including Taking the Pulse® Europe, Taking the Pulse® Asia, ePharma Physician®, Cybercitizen® Health, Cybercitizen® Health Europe, and ePharma Consumer®. Each study serves a unique purpose and focuses on different aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analysis among more than 80 consumer therapeutic segments and 25 physician specialist segments.

Manhattan Research is a leading market research and advisory firm for pharmaceutical and healthcare companies. For more information or to schedule an analyst interview, please contact

Maureen Malloy


Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
2. Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007
3. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
4. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
5. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
6. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
7. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
8. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
9. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
10. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
11. American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Post Your Comments:
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... NORTH CHICAGO, Ill. , Nov. 30, 2015 /PRNewswire/ ... an all-inclusive program that focuses on a daily routine ... how patients take their medication can affect the way ... establish and follow to their a daily routine are ... is to help patients better manage their hypothyroidism ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
Breaking Biology News(10 mins):